Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

722 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Crohn's disease: beyond antagonists of tumour necrosis factor.
Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Colombel JF. Peyrin-Biroulet L, et al. Lancet. 2008 Jul 5;372(9632):67-81. doi: 10.1016/S0140-6736(08)60995-2. Lancet. 2008. PMID: 18603161 Review.
NODs in defence: from vulnerable antimicrobial peptides to chronic inflammation.
Peyrin-Biroulet L, Vignal C, Dessein R, Simonet M, Desreumaux P, Chamaillard M. Peyrin-Biroulet L, et al. Trends Microbiol. 2006 Oct;14(10):432-8. doi: 10.1016/j.tim.2006.08.008. Epub 2006 Aug 30. Trends Microbiol. 2006. PMID: 16942880
Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander?
Peyrin-Biroulet L, Chamaillard M, Gonzalez F, Beclin E, Decourcelle C, Antunes L, Gay J, Neut C, Colombel JF, Desreumaux P. Peyrin-Biroulet L, et al. Gut. 2007 Apr;56(4):577-83. doi: 10.1136/gut.2005.082925. Epub 2006 Sep 6. Gut. 2007. PMID: 16956921 Free PMC article. Review. No abstract available.
Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.
Peyrin-Biroulet L, Laclotte C, Bigard MA. Peyrin-Biroulet L, et al. Aliment Pharmacol Ther. 2007 Mar 15;25(6):675-80. doi: 10.1111/j.1365-2036.2007.03254.x. Aliment Pharmacol Ther. 2007. PMID: 17311600 Clinical Trial.
How NOD2 mutations predispose to Crohn's disease?
Vignal C, Singer E, Peyrin-Biroulet L, Desreumaux P, Chamaillard M. Vignal C, et al. Microbes Infect. 2007 Apr;9(5):658-63. doi: 10.1016/j.micinf.2007.01.016. Epub 2007 Jan 27. Microbes Infect. 2007. PMID: 17379562 Review.
NOD2 and defensins: translating innate to adaptive immunity in Crohn's disease.
Peyrin-Biroulet L, Chamaillard M. Peyrin-Biroulet L, et al. J Endotoxin Res. 2007;13(3):135-9. doi: 10.1177/0968051907080429. J Endotoxin Res. 2007. PMID: 17621555 Review.
[Anti-TNF therapy and Crohn's disease].
Peyrin-Biroulet L. Peyrin-Biroulet L. Gastroenterol Clin Biol. 2008 May;32(5 Pt 1):478-81. doi: 10.1016/j.gcb.2008.03.004. Epub 2008 Apr 24. Gastroenterol Clin Biol. 2008. PMID: 18439777 French. No abstract available.
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.
Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Peyrin-Biroulet L, et al. Clin Gastroenterol Hepatol. 2008 Jun;6(6):644-53. doi: 10.1016/j.cgh.2008.03.014. Clin Gastroenterol Hepatol. 2008. PMID: 18550004
Early combined immunosuppression in Crohn's disease.
Danese S, Peyrin-Biroulet L. Danese S, et al. Lancet. 2008 Jun 14;371(9629):1996; author reply 1996-7. doi: 10.1016/S0140-6736(08)60862-4. Lancet. 2008. PMID: 18555908 No abstract available.
Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience.
Oussalah A, Babouri A, Chevaux JB, Stancu L, Trouilloud I, Bensenane M, Boucekkine T, Bigard MA, Peyrin-Biroulet L. Oussalah A, et al. Aliment Pharmacol Ther. 2009 Feb 15;29(4):416-23. doi: 10.1111/j.1365-2036.2008.03902.x. Epub 2008 Nov 25. Aliment Pharmacol Ther. 2009. PMID: 19035976
722 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback